Go to:
Logótipo
Você está em: Start > Publications > View > Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension
Map of Premises
Principal
Publication

Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension

Title
Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension
Type
Article in International Scientific Journal
Year
2001
Authors
pestana, m
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
jardim, h
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
correia, f
(Author)
FCNAUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
vieira-coelho, ma
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
soares-da-silva, p
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 16
Pages: 53-59
ISSN: 0931-0509
Scientific classification
FOS: Medical and Health sciences > Clinical medicine
Other information
Authenticus ID: P-000-XJD
Abstract (EN): The present report addresses the status of the renal dopaminergic system activity in patients afflicted with different renal disorders and in the remnant kidney of uninephrectomized (UNX) rats, based on the urinary excretion of L-DOPA, dopamine and amine metabolites. In renal transplant recipients with good recovery of graft function (group 1, n = 11), the daily urinary excretion of DOPAC, but not that of HVA, was found to increase progressively throughout the first 12 days post-transplantation from 698 +/- 57 nmol in the first day to 3498 +/- 414 nmol on day 9, and then remained constant until day 12. This resulted in a 6-fold increase in the urinary DOPAC/dopamine ratios. In renal transplant recipients with acute tubular necrosis (group 2, n = 8), the urinary levels of dopamine, DOPAC and HVA were similar to 30% of those in group 1. Tn a group of 28 patients with chronic renal parenchymal disorders, the daily urinary excretion of L-DOPA, free dopamine and dopamine metabolites (DOPAC and HVA) correlated positively with the degree of deterioration of renal function (P<0.01). However, the UDopamine/L-DOPA and U-DOPAC/Dopamine ratios in patients with chronic renal insufficiency were found to be similar to those observed in patients with normal renal function. In 14 IgA nephropathy (IgA-N) patients with near normal renal function, the changes in 24 h mean blood pressure when going from 20 to 350 mmol/day sodium intake correlated negatively with the daily urinary excretion of dopamine (r(2)=0.597, P<0.01). The urinary excretion of L-DOPA and dopamine in IgA-N patients with salt-sensitive (SS) blood pressure was lower than in salt-resistant (SR) patients (P<0.05), irrespective of their daily sodium intake. However, the rise in urinary dopamine output during salt loading (from 20 to 350 mmol/day) was greater (P<0.05) in IgA-N SS patients (21.2+/-2.5% increase) than in SR patients (6.3+/-1.4% increase). Fifteen days after the surgery, uninephrectomy (UNX) in the rat was accompanied by an enhanced (P<0.05) urinary excretion of dopamine (36+/-3 vs 26+/-2), DOPAC (124+/-11 vs 69+/-6) and HVA (611+/-42 vs 354+/-7) (nmol/g kidney/kg body weight). This was accompanied by an increase in V-max values for renal aromatic L-amino acid decarboxylase in the remnant kidney of UNX rats (P<0.05). Sch 23390, a D-1 dopamine receptor antagonist, produced a marked reduction in the urinary excretion of sodium in UNX rats, whereas in sham-operated rats the decrease in urinary sodium did not attain a significant difference. It is concluded that the study of the renal dopaminergic system in patients afflicted with renal parenchymal disorders should address parameters other than free urinary dopamine, namely the urinay excretion of L-DOPA and dopamine metabolites (DOPAC and HVA). It is also suggested that in SS hypertension of chronic renal parenchymal diseases, renal dopamine produced in the residual tubular units may be enhanced during a sodium challenge, thus behaving appropriately as a compensatory natriuretic hormone.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 7
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

The association between TNFRSF1B rs1061624 polymorphism and hypertension in end-stage kidney disease patients on dialysis (2024)
Another Publication in an International Scientific Journal
Belo, L; Santos-Silva, A; Catarino, C; Bronze da Rocha, E
Short-term effects of gadolinium and gadoteric acid on kidney – impact on inflammation (2024)
Another Publication in an International Scientific Journal
Belo, L; Santos-Silva, A; Catarino, C; Bronze da Rocha, E
Prolonged use of an intracardiac catheter for dialysis in a patient with multiple venous access failure (2006)
Another Publication in an International Scientific Journal
Santos Araujo, C; Casanova, J; Carvalho, B; Pestana M
Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review (2012)
Another Publication in an International Scientific Journal
Salgado, TM; Moles, R; Benrimoj, SI; Fernandez Llimos, F
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations (2009)
Another Publication in an International Scientific Journal
Oqvist, B; Brenner, BM; João Paulo Oliveira; Ortiz, A; Schaefer, R; Svarstad, E; Wanner, C; Zhang, K; Warnock, DG

See all (71)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2025-07-08 at 01:35:09 | Acceptable Use Policy | Data Protection Policy | Complaint Portal